Summary:allogeneic BMT in CR1 and developed EBV-LPD 1.5 months later. Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexamethasone) A patient with AML (FAB M4Eo) developed EBV-LPD 1.5 months after allogeneic BMT from his one locusfollowed by EBV-CTL infusions were unsuccessful. In addition, our patient developed EBV-LPD after receiving mismatched mother, the diagnosis being confirmed on day +82. Attempts to eradicate the monoclonally prolimarrow from his one locus-mismatched mother, and not from an unrelated donor or a haploidentical donor utilizing ferating LPD using chemotherapy (VP16/dexamethasone) followed by two doses of EBV-specific CTL T-lymphocyte depletion which is unusual, because there are very few EBV-LPD cases who have received marrow from and one dose of unstimulated donor leukocytes were not successful. We assume delay of infusions (day +100, one locus-mismatched related donors. Irradiated lymphoblastic cells prepared from 10 ml of +107) and insufficient CTL cell doses (total 9.2 × 10 6 ) may have been responsible for the poor outcome in heparinized recipient peripheral blood (PB) were used as targets. One hundred milliliters of heparinized donor PB this case.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.